

Organization	Name of Organization / 会社名
	BioCardia, Inc.
	URL
	www.biocardia.com
	Brief Descriptions of Organization / 会社概要
	<p>BioCardia is a clinical-stage regenerative medicine company.</p> <p>Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.</p> <p>Our Pipeline: Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia. CardiAMP is under Phase III pivotal trials in USA and its cell therapy system is approved in Japan today.</p> <p>Our second therapeutic candidate is the investigational CardiALLO™ Cell Therapy System, an allogeneic culture expanded "off the shelf" NK1+ cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.</p> <p>We also have the world's leading delivery system as demonstrated through published scientific data for these therapies.</p>

Oral Presentation	Title of Presentation / 講演タイトル
	CardiAMP Cell Therapy for the Treatment of Heart Failure
	Abstract / 要旨
	<p>The investigational CardiAMP™ Therapy is designed to be a comprehensive biotherapeutic heart failure and chronic myocardial ischemia solution (two indications) , incorporating: (1) a proprietary molecular diagnostic to characterize the potency of a patient's own bone marrow cells and determine if they are an optimal candidate for therapy (2) a point of care processing platform to prepare cells at the patient's bedside (3) an optimized therapeutic formulation that builds on the total experience in the cardiac stem cell field to-date, and (4) a proprietary interventional delivery system that easily navigates a patient's vasculature to securely deliver the specific dosage of cells in a routine cardiac catheterization procedure.</p> <p>Product is under investigational pivotal trials in the United States and elements of the system are approved for sale in USA, EU, and Japan.</p>
	Objectives and/or Motives / 目的
	<p>We seek a partner to advance CardiAMP cell therapy through an anticipated small trial in Japan for conditional approval and commercialization in parallel to our activities in the United States.</p>